These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26359448)

  • 1. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
    Mayor S
    BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
    [No Abstract]   [Full Text] [Related]  

  • 2. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
    [No Abstract]   [Full Text] [Related]  

  • 3. UK PrEP decision re-ignites HIV activism.
    The Lancet
    Lancet; 2016 Apr; 387(10027):1484. PubMed ID: 27115959
    [No Abstract]   [Full Text] [Related]  

  • 4. Is sub-Saharan Africa ready for pre-exposure prophylaxis?
    Bernier A; Gapiya J; Sylla A; Anoma C; Somda M; Dah E; Aranda JF; Himmich H
    Lancet HIV; 2016 Apr; 3(4):e154-5. PubMed ID: 27036989
    [No Abstract]   [Full Text] [Related]  

  • 5. Better late than never: PrEP in England.
    The Lancet Hiv
    Lancet HIV; 2017 Jan; 4(1):e1. PubMed ID: 28007341
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
    Baker J; OʼHara KM
    JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to "PrEP" for HIV Prevention in Women.
    Ntim GJ; Kransdorf LN
    J Womens Health (Larchmt); 2017 Feb; 26(2):195-196. PubMed ID: 28140756
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
    AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
    Jewsbury S; Ward C
    Int J STD AIDS; 2020 Jan; 31(1):85-87. PubMed ID: 31801029
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
    Wang X; Nutland W; Brady M; Green I; Boffito M; McClure M
    Int J STD AIDS; 2019 Jul; 30(8):765-768. PubMed ID: 31072205
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM
    Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PrEP: why are we waiting?
    Lancet HIV
    Lancet HIV; 2015 Oct; 2(10):e401. PubMed ID: 26423641
    [No Abstract]   [Full Text] [Related]  

  • 13. The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.
    Dunn DT; Glidden DV; Stirrup OT; McCormack S
    Lancet HIV; 2018 Jun; 5(6):e329-e334. PubMed ID: 29893246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Welcome to the preexposure prophylaxis revolution.
    Baeten J; McCormack S
    Curr Opin HIV AIDS; 2016 Jan; 11(1):1-2. PubMed ID: 26633637
    [No Abstract]   [Full Text] [Related]  

  • 15. Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19.
    Quirke S; Quinn L; Hegarty D; Loy A; Lyons F; Mulcahy F; Devitt E
    Int J STD AIDS; 2021 Jan; 32(1):100-103. PubMed ID: 33050787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
    Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ
    AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.
    Haaland RE; Martin A; Holder A; Fountain JJ; Hall L; Pescatore NA; Heeke S; Kelley CF
    AIDS; 2017 Jul; 31(11):1647-1650. PubMed ID: 28657968
    [No Abstract]   [Full Text] [Related]  

  • 18. Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
    Conniff J; Evensen A
    J Am Board Fam Med; 2016; 29(1):143-51. PubMed ID: 26769887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
    Yacoub R; Nadkarni GN; Weikum D; Konstantinidis I; Boueilh A; Grant RM; Mugwanya KK; Baeten JM; Wyatt CM
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):e115-8. PubMed ID: 26627105
    [No Abstract]   [Full Text] [Related]  

  • 20. Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project.
    Doblecki-Lewis S; Liu AY; Feaster DJ; Cohen SE; Elion R; Bacon O; Coleman M; Cardenas G; Kolber MA
    J Acquir Immune Defic Syndr; 2018 Sep; 79(1):62-69. PubMed ID: 29771790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.